CN118078810A - 用于抑制肿瘤生长的材料和方法 - Google Patents

用于抑制肿瘤生长的材料和方法 Download PDF

Info

Publication number
CN118078810A
CN118078810A CN202410201525.5A CN202410201525A CN118078810A CN 118078810 A CN118078810 A CN 118078810A CN 202410201525 A CN202410201525 A CN 202410201525A CN 118078810 A CN118078810 A CN 118078810A
Authority
CN
China
Prior art keywords
cancer
free amino
formulation
amino acids
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202410201525.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·维德亚瑟格
R·古普塔
S·加托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entelinco LLC
University of Florida Research Foundation Inc
Original Assignee
Entelinco LLC
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entelinco LLC, University of Florida Research Foundation Inc filed Critical Entelinco LLC
Publication of CN118078810A publication Critical patent/CN118078810A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202410201525.5A 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法 Pending CN118078810A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762566787P 2017-10-02 2017-10-02
US62/566,787 2017-10-02
PCT/US2018/054015 WO2019070750A1 (en) 2017-10-02 2018-10-02 MATERIALS AND METHODS FOR INHIBITING TUMOR GROWTH
CN201880076756.0A CN111417391B (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880076756.0A Division CN111417391B (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Publications (1)

Publication Number Publication Date
CN118078810A true CN118078810A (zh) 2024-05-28

Family

ID=64049688

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202410201525.5A Pending CN118078810A (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法
CN201880076756.0A Active CN111417391B (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880076756.0A Active CN111417391B (zh) 2017-10-02 2018-10-02 用于抑制肿瘤生长的材料和方法

Country Status (7)

Country Link
US (1) US12109191B2 (https=)
EP (1) EP3691628A1 (https=)
JP (2) JP7352901B2 (https=)
KR (1) KR102709096B1 (https=)
CN (2) CN118078810A (https=)
CA (1) CA3078335A1 (https=)
WO (1) WO2019070750A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700087359A1 (it) 2017-07-28 2019-01-28 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nel trattamento di malattie associate a disfunzione mitocondriale
EP3796922B1 (en) * 2018-05-22 2026-03-18 Seleq Oy Pharmaceutical compositions comprising a seleno amino acid compound for use in combination with another agent for the treatment of liver or pancreas cancer
IT201800006725A1 (it) 2018-06-27 2019-12-27 Composizioni comprendenti aminoacidi per l'uso nella prevenzione e nel trattamento di malattie epatiche
IT201900002109A1 (it) 2019-02-13 2020-08-13 Professional Dietetics Spa Composizioni comprendenti amminoacidi per l'uso nel trattamento di lesioni del sistema nervoso centrale
IT202000000454A1 (it) * 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per la prevenzione e il trattamento del cancro
IT202000000442A1 (it) 2020-01-13 2021-07-13 Professional Dietetics Spa Composizioni comprendenti amino acidi per l'uso nella prevenzione e nel trattamento di effetti collaterali della chemioterapia
JP2023531872A (ja) * 2020-05-29 2023-07-26 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 急性呼吸窮迫症候群、喘息、又はアレルギー性鼻炎を治療するための製剤及び方法
CN115192564B (zh) * 2022-05-23 2023-11-17 四川大学华西医院 一种苯丙氨酸衍生物、药物组合物及其在肿瘤治疗中的应用
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH01301619A (ja) * 1988-05-30 1989-12-05 Otsuka Pharmaceut Factory Inc 癌用アミノ酸製剤
JPH0368514A (ja) * 1989-08-09 1991-03-25 Morishita Pharmaceut Co Ltd 癌用アミノ酸製剤
WO1993006934A1 (en) 1991-09-30 1993-04-15 Devtech Labs, Inc. Electrostatic separation of plastic materials
KR0172193B1 (ko) * 1991-10-07 1999-02-01 오오쓰까 아끼히꼬 암 치료용 경장제제
US5658895A (en) 1991-10-07 1997-08-19 Otsuka Pharmaceutical Factory, Inc. Anticancer enteral feeding composition
JP3429327B2 (ja) * 1992-07-20 2003-07-22 味の素ファルマ株式会社 癌用アミノ酸輸液剤
JPH06256184A (ja) * 1993-03-05 1994-09-13 Morishita Roussel Kk 癌患者用アミノ酸製剤
JP4683881B2 (ja) 2003-08-27 2011-05-18 有限会社アーク技研 抗腫瘍活性剤
US20050176807A1 (en) * 2004-02-09 2005-08-11 Friesen Kim G. Composition and method for use in cartilage affecting conditions
AU2005308538A1 (en) * 2004-08-09 2006-06-01 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of health problems that result from underlying metabolic disorders
KR101758424B1 (ko) 2010-09-24 2017-07-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
WO2015003021A2 (en) * 2013-07-01 2015-01-08 The Trustees Of Princeton University Dietary supplements and composition for treating cancer
US10973251B1 (en) 2015-09-21 2021-04-13 The Board Of Trustees Of The Leland Stanford Junior University Nutritional treatment for cancer

Also Published As

Publication number Publication date
KR102709096B1 (ko) 2024-09-23
JP2023171755A (ja) 2023-12-05
WO2019070750A1 (en) 2019-04-11
CA3078335A1 (en) 2019-04-11
JP2020536096A (ja) 2020-12-10
KR20200060492A (ko) 2020-05-29
CN111417391B (zh) 2024-06-18
CN111417391A (zh) 2020-07-14
JP7352901B2 (ja) 2023-09-29
EP3691628A1 (en) 2020-08-12
US12109191B2 (en) 2024-10-08
US20200323820A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
JP7352901B2 (ja) 腫瘍成長を阻害するための材料および方法
US20240166668A1 (en) Compounds and uses thereof
JP7017509B2 (ja) がんを治療するための四環式キノロン類似体の併用療法
US9526915B2 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
US20230398119A1 (en) Combination therapy involving diaryl macrocyclic compounds
CN110062621A (zh) 氨基酸组合物及其用途
AU2018242612B2 (en) Dose and regimen for an HDM2-p53 interaction inhibitor in hematological tumors
US10882863B2 (en) Compounds for reducing c-Myc in c-Myc overexpressing cancers background
US20230072053A1 (en) Compounds and uses thereof
WO2023200800A1 (en) Methods of treating androgen receptor-independent prostate cancer
CN110312508A (zh) 含有棉酚和苯乙双胍作为活性成分的预防和治疗胰腺癌的药物组合物
CN117377492A (zh) 包含蛋白激酶抑制剂的药物组合物及其医药用途
US20240122937A1 (en) Treating cancer in patient with pten inactivating mutation
EP3949970A1 (en) Combined use of a-nor-5? androstane compound drug and anticancer drug
AU2024343230A1 (en) Combination of a wee1 inhibitor and a pkmyt1 inhibitor
WO2016111957A1 (en) Chloroquinoline triazole compounds, composition and uses
HK40008907A (en) Pharmaceutical composition for preventing and treating pancreatic cancer, containing gossypol and phenformin as active ingredients
HK40012947A (en) Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Florida, USA

Applicant after: University OF FLORIDA RESEARCH FOUNDATION, INC.

Applicant after: Amylev Limited

Address before: Florida, USA

Applicant before: University OF FLORIDA RESEARCH FOUNDATION, INC.

Country or region before: U.S.A.

Applicant before: Entelinco LLC

CB02 Change of applicant information